27 sierpnia, 2020
Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins
Ebola Virus Illness Survivors Present Extra Environment friendly Antibody Immunity than Vaccinees Regardless of Comparable Ranges of Circulating Immunoglobulins
The final seven years have seen the best surge of Ebola virus illness (EVD) circumstances in equatorial Africa, together with the 2013-2016 epidemic in West Africa and the latest epidemics within the Democratic Republic of Congo (DRC). The vaccine scientific trials that befell in West Africa and the DRC, in addition to follow-up research in collaboration with EVD survivor communities, have for the primary time allowed researchers to check immune reminiscence induced by pure an infection and vaccination.
These comparisons could also be related to guage the putative effectiveness of vaccines and candidate medical countermeasures corresponding to convalescent plasma switch.
On this research, we in contrast the long-term performance of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who obtained the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) throughout the Section I scientific trial in Hamburg.
Our research highlights necessary variations between EBOV vaccination and pure an infection and offers a framework for comparability with different vaccine candidates.
cDNA
 Anti-Mouse IL-1 R2 Antibody |
|||
| 103-M138 | ReliaTech | 100 µg | EUR 399 |
|
Description: IL-1 receptor type II (IL1R-II) is a 65 kD member of the immunoglobulin superfamily also known as IL-1 receptor (IL1R) type II. The IL1R family is composed of three proteins: IL1R type I, IL1-RII, and the widely expressed IL-1RAcP. |
|||
 LumiAb ELISA Kit) IL-1 R2 (Human) LumiAb ELISA Kit |
|||
| MBS9510883-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 4355 |
IL-1 R2 (Human) LumiAb ELISA Kit |
|||
| MBS9510883-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 2225 |
IL-1 R2 (Human) LumiAb ELISA Kit |
|||
| MBS9510883-96StripWells | MyBiosource | 96-Strip-Wells | EUR 500 |
 OmniKine ELISA Kit) IL-1 R2 (Human) OmniKine ELISA Kit |
|||
| MBS9501955-1x96Wells | MyBiosource | 1x96Wells | EUR 500 |
IL-1 R2 (Human) OmniKine ELISA Kit |
|||
| MBS9501955-5x96Wells | MyBiosource | 5x96Wells | EUR 2300 |
 Sandwich ELISA Kit) IL-1 R2 (Human) Sandwich ELISA Kit |
|||
| OK-0229 | Assay Biotech | 1Kit | EUR 280 |
|
Description: IL-1 R2 (Human) Colorimetric Sandwich ELISA Kit |
|||
 : 96 Wells (OKAG00129)) IL-1 R2 ELISA Kit (Human) : 96 Wells (OKAG00129) |
|||
| OKAG00129 | Aviva Systems Biology | 96 Wells | EUR 715.2 |
|
Description: Description of target: The protein encoded by this gene is a cytokine receptor that belongs to the interleukin 1 receptor family. This protein binds interleukin alpha (IL1A), interleukin beta (IL1B), and interleukin 1 receptor, type I(IL1R1/IL1RA), and acts as a decoy receptor that inhibits the activity of its ligands. Interleukin 4 (IL4) is reported to antagonize the activity of interleukin 1 by inducing the expression and release of this cytokine. This gene and three other genes form a cytokine receptor gene cluster on chromosome 2q12. Alternative splicing results in multiple transcript variants and protein isoforms. Alternative splicing produces both membrane-bound and soluble proteins. A soluble protein is also produced by proteolytic cleavage.;Species reactivity: Human;Application: ELISA;Assay info: Quantitative Colorimentric Sandwich ELISA;Sensitivity: 32 pg/mL |
|||
 IL 1 R2 Recombinant Protein |
|||
| 96-436 | ProSci | 0.1 mg | EUR 619.8 |
|
Description: Interleukin-1 receptor type 2 (IL1R2) is also known as CD121 antigen-like family member B (CDw121b), IL-1 type II receptor, Interleukin-1 receptor type II, belongs to the interleukin-1 receptor family. Two distinct types of IL1 receptors which are able to bind IL1 specifically have been identified, designated as IL1RI (IL1RA) and IL1RII (IL1RB). IL1R2 is non-signaling receptor for IL1A, IL1B and IL1RN, reduces IL1B activities. Serves as a decoy receptor by competetive binding to IL1B and preventing its binding to IL1R1. IL1R2 modulates cellular response through non-signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly IL1A and IL1RN. The secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted/soluble receptors. |
|||
 Mouse Anti Human IL-1 beta |
|||
| MBS140161-05mg | MyBiosource | 0.5mg | EUR 440 |
Mouse Anti Human IL-1 beta |
|||
| MBS140161-1mg | MyBiosource | 1mg | EUR 600 |
Mouse Anti Human IL-1 beta |
|||
| MBS140161-5x1mg | MyBiosource | 5x1mg | EUR 2375 |
 Recombinant Mouse IL-1 R2/IL-1 RII Protein |
|||
| RP00726 | Abclonal | 10μg | EUR 136.5 |
|
|||
Recombinant Mouse IL-1 R2/IL-1 RII Protein |
|||
| RP00729 | Abclonal | 10μg | EUR 138.16 |
 Anti‐Human IL‐17A |
|||
| E2790213 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
 Mouse Anti Human IL-1 beta FITC |
|||
| MBS140163-05mg | MyBiosource | 0.5mg | EUR 440 |
Mouse Anti Human IL-1 beta FITC |
|||
| MBS140163-1mg | MyBiosource | 1mg | EUR 600 |
Mouse Anti Human IL-1 beta FITC |
|||
| MBS140163-5x1mg | MyBiosource | 5x1mg | EUR 2375 |
) human anti-human IL-1 β mAb(14) |
|||
| E4A09D02-14 | EnoGene | 50ug | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
) human anti-human IL-1 β mAb(7Z) |
|||
| E4A09D02-7Z | EnoGene | 50ug | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
 Monoclonal Mouse anti Human IL-1 beta |
|||
| MBS550073-05mg | MyBiosource | 0.5mg | EUR 595 |
Monoclonal Mouse anti Human IL-1 beta |
|||
| MBS550073-1mg | MyBiosource | 1mg | EUR 915 |
 Mouse Anti Human IL-1 beta Biotinylated |
|||
| MBS140162-05mg | MyBiosource | 0.5mg | EUR 440 |
Mouse Anti Human IL-1 beta Biotinylated |
|||
| MBS140162-1mg | MyBiosource | 1mg | EUR 600 |
Mouse Anti Human IL-1 beta Biotinylated |
|||
| MBS140162-5x1mg | MyBiosource | 5x1mg | EUR 2375 |
) TNF-R2 (human) |
|||
| TN-004 | Kamiya Biomedical Company | 50 µg | EUR 738 |
 anti-PKA R2 |
|||
| YF-PA13990 | Abfrontier | 50 ul | EUR 435.6 |
|
Description: Mouse polyclonal to PKA R2 |
|||
anti-PKA R2 |
|||
| YF-PA24454 | Abfrontier | 50 ul | EUR 400.8 |
|
Description: Mouse polyclonal to PKA R2 |
|||
 human anti-human IL-2 mAb |
|||
| E409C12-h100 | EnoGene | 100μL | EUR 395 |
|
Description: Available in various conjugation types. |
|||
 human anti-human IL-4 mAb |
|||
| E409C13-h100 | EnoGene | 100μL | EUR 395 |
|
Description: Available in various conjugation types. |
|||
 human anti-human IL-5 mAb |
|||
| E409C14-h100 | EnoGene | 100μL | EUR 395 |
|
Description: Available in various conjugation types. |
|||
 human anti-human IL-8 mAb |
|||
| E409C16-h100 | EnoGene | 100μL | EUR 395 |
|
Description: Available in various conjugation types. |
|||
human anti-human IL-5 mAb |
|||
| E4A09D05 | EnoGene | 50ug | EUR 255 |
|
Description: Available in various conjugation types. |
|||
 Human anti-Human IL-2 mAb |
|||
| MBS8576800-005mg | MyBiosource | 0.05mg | EUR 325 |
Human anti-Human IL-2 mAb |
|||
| MBS8576800-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Human anti-Human IL-2 mAb |
|||
| MBS8576800-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Human anti-Human IL-2 mAb |
|||
| MBS8576800-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Human anti-Human IL-2 mAb |
|||
| MBS8576800-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
 Human anti-Human IL-4 mAb |
|||
| MBS8576802-005mg | MyBiosource | 0.05mg | EUR 325 |
Human anti-Human IL-4 mAb |
|||
| MBS8576802-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Human anti-Human IL-4 mAb |
|||
| MBS8576802-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Human anti-Human IL-4 mAb |
|||
| MBS8576802-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Human anti-Human IL-4 mAb |
|||
| MBS8576802-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
 Human anti-Human IL-5 mAb |
|||
| MBS8576804-005mg | MyBiosource | 0.05mg | EUR 325 |
Human anti-Human IL-5 mAb |
|||
| MBS8576804-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Human anti-Human IL-5 mAb |
|||
| MBS8576804-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Human anti-Human IL-5 mAb |
|||
| MBS8576804-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Human anti-Human IL-5 mAb |
|||
| MBS8576804-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
 Human anti-Human IL-8 mAb |
|||
| MBS8576808-005mg | MyBiosource | 0.05mg | EUR 325 |
Human anti-Human IL-8 mAb |
|||
| MBS8576808-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Human anti-Human IL-8 mAb |
|||
| MBS8576808-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Human anti-Human IL-8 mAb |
|||
| MBS8576808-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Human anti-Human IL-8 mAb |
|||
| MBS8576808-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
 human anti-human IL-1β mAb |
|||
| E409C11-h100 | EnoGene | 100μL | EUR 395 |
|
Description: Available in various conjugation types. |
|||
 human anti-human IL-10 mAb |
|||
| E409C17-h100 | EnoGene | 100μL | EUR 395 |
|
Description: Available in various conjugation types. |
|||
 Human anti-Human IL-10 mAb |
|||
| MBS8576810-005mg | MyBiosource | 0.05mg | EUR 325 |
Human anti-Human IL-10 mAb |
|||
| MBS8576810-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Human anti-Human IL-10 mAb |
|||
| MBS8576810-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Human anti-Human IL-10 mAb |
|||
| MBS8576810-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Human anti-Human IL-10 mAb |
|||
| MBS8576810-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
 Human anti-Human IL-1beta mAb |
|||
| MBS8576798-005mg | MyBiosource | 0.05mg | EUR 325 |
Human anti-Human IL-1beta mAb |
|||
| MBS8576798-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Human anti-Human IL-1beta mAb |
|||
| MBS8576798-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Human anti-Human IL-1beta mAb |
|||
| MBS8576798-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Human anti-Human IL-1beta mAb |
|||
| MBS8576798-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
) human anti-human IL-12/IL-23 p40 mAb(3H2) |
|||
| E4A09D33-3H2 | EnoGene | 50ug | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
) human anti-human IL-12/IL-23 p40 mAb(5N9) |
|||
| E4A09D33-5N9 | EnoGene | 50ug | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
) human anti-human IL-12/IL-23 p40 mAb(1G11) |
|||
| E4A09D33-1G11 | EnoGene | 50ug | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
 Anti-Human TGF beta R2 Antibody |
|||
| 101-M178 | ReliaTech | 100 µg | EUR 399 |
|
Description: Most cell types express three sizes of receptors for TGF-beta. These are designated Type I (53 kDa), Type II (70 - 85 kDa), and Type III (250 - 350 kDa). The Type I receptor is a membrane-bound serine/threonine kinase that apparently requires the presence of the Type II receptor to bind TGF-beta. The Type II receptor is also a membrane-bound serine/threonine kinase that binds TGF-beta1 and TGF-beta 3 with high affinity and TGF-beta 2 with much lower affinity. The Type I and Type II receptors together form a heterodimeric signaling complex that is essential for the transduction of the anti-proliferative signals of TGF-beta. The Type III receptor is a transmembrane proteoglycan with a large extracellular domain and a 43 amino acid residue cytoplasmic domain. The cytoplasmic domain of the Type III receptor lacks an obvious signaling motif and the receptor may not be involved directly in signal transduction. |
|||
 Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|||
| MBS2543245-006mL | MyBiosource | 0.06mL | EUR 250 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|||
| MBS2543245-012mL | MyBiosource | 0.12mL | EUR 370 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|||
| MBS2543245-02mL | MyBiosource | 0.2mL | EUR 550 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|||
| MBS2543246-006mL | MyBiosource | 0.06mL | EUR 250 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|||
| MBS2543246-012mL | MyBiosource | 0.12mL | EUR 370 |
Mouse anti Human IL-1RAcP/IL-1R3 Monoclonal Antibody |
|||
| MBS2543246-02mL | MyBiosource | 0.2mL | EUR 550 |
 ApoE R2, Recombinant Human |
|||
| MBS636329-005mg | MyBiosource | 0.05mg | EUR 880 |
ApoE R2, Recombinant Human |
|||
| MBS636329-5x005mg | MyBiosource | 5x0.05mg | EUR 3730 |
 Mouse Monoclonal anti-human FGF-R2 |
|||
| hAP-0278 | Angio Proteomie | 100ug | EUR 250 |
Mouse Monoclonal anti-human FGF-R2 |
|||
| hAP-0278A | Angio Proteomie | 100ug | EUR 250 |
 Mouse Monoclonal anti-human Orexin R2 |
|||
| hAP-0850 | Angio Proteomie | 50ug | EUR 400 |
) MOUSE ANTI HUMAN CD126 (IL-6R) |
|||
| MBS213171-01mg | MyBiosource | 0.1mg | EUR 355 |
MOUSE ANTI HUMAN CD126 (IL-6R) |
|||
| MBS213171-5x01mg | MyBiosource | 5x0.1mg | EUR 1425 |
) human anti-human IL-2 mAb (D1) |
|||
| E4A09D03-A7C | EnoGene | 50ug | EUR 255 |
|
Description: Available in various conjugation types. |
|||
) human anti-human IL-2 mAb (F5) |
|||
| E4A09D03-B1F | EnoGene | 50ug | EUR 255 |
|
Description: Available in various conjugation types. |
|||
Mechanism of Antibodies Purification by Protein A
Protein A, a serious cell wall part of Staphylococcus aureus, is likely one of the first immunoglobulin-binding proteins that’s found about 80 years in the past. Nonetheless, an excessive amount of improvement in each purification strategies and software of antibodies in therapy have been executed.
There are numerous publications primarily based on the untargeted (dimension exclusion, ion alternate and hydrophobic interactions) and focused (affinity) strategies by scientists in tutorial/trade teams. On this evaluate, now we have centered on the research of each native and engineered Protein A to grasp its mechanism within the purification of antibodies.
What area of Protein A dose work together with antibody? The place are contact areas? What’s the non-covalent interplay mechanism of Protein A and antibody? Does alkaline situation, within the washing step, affect on antibody construction and exercise? Then again, the immobilization of Protein A on numerous sorbents corresponding to agarose, silica, polysaccharide, polymers, and magnetic nanoparticles have investigated.
Additionally, the appliance of Protein A as biosensor for detection of the antibody is mentioned. We’ve got tried to seek out fascinating and stimulating solutions to all these questions.
Selective elimination of human pluripotent stem cells by Anti-Dsg2 antibody-doxorubicin conjugates
The self-renewal properties of human pluripotent stem cells (hPSCs) contribute to their efficacy in tissue regeneration purposes but improve the probability of teratoma formation, thereby limiting their scientific utility. To deal with this difficulty, we developed a device to particularly goal and neutralize undifferentiated hPSCs, thereby minimizing tumorigenicity danger with out negatively affecting regenerated and somatic tissues.
Particularly, we conjugated a monoclonal antibody (K6-1) beforehand generated in our laboratory in opposition to desmoglein 2 (Dsg2), which is extremely differentially expressed in undifferentiated hPSCs versus somatic tissues, to the chemotherapeutic agent doxorubicin (DOX).
The K6-1-DOX conjugates had been selectively focused and included into Dsg2-positive hPSCs, resulting in pH-dependent endosomal launch and nuclear localization of DOX with subsequent cytotoxicity by way of an apoptotic caspase cascade. Conversely, Dsg2-negative fibroblasts confirmed minimal conjugate uptake or cytotoxicity, suggesting that K6-1-DOX therapy would yield few unintended effects owing to off-target results.
Selective elimination of undifferentiated stem cells was additionally supported by in vivo research utilizing a mouse xenograft mannequin, whereby hIgG-DOX- however not K6-1-DOX-pretreated-hPSC injection led to teratoma improvement. Collectively, these outcomes validated the flexibility of the Dsg2-targeted antibody-anticancer drug conjugate to facilitate the security of stem cell therapies.
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Most cancers Remedy
Breast most cancers is the most typical invasive tumor in girls and the second main reason behind cancer-related loss of life. Nanomedicine raises excessive expectations for hundreds of thousands of sufferers as it might probably present higher, extra environment friendly, and reasonably priced healthcare, and it has the potential to develop novel therapeutics for the therapy of strong tumors.
On this regard, focused therapies will be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors via conjugation with antibodies-the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can protect the chemical construction of medicine, ship them in a managed method, and cut back toxicity.
As sure breast most cancers subtypes and indications have restricted therapeutic choices, this discipline offers hope for the long run therapy of sufferers with troublesome to deal with breast cancers. On this evaluate, we talk about the appliance of ACNPs for the therapy of this illness. Given the truth that ACNPs have proven scientific exercise on this scientific setting, particular emphasis on the function of the nanovehicles and their translation to the clinic is positioned on the revision.
 (APC)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (APC) |
|||
| MBS6269705-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (APC) |
|||
| MBS6269705-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (HRP)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (HRP) |
|||
| MBS6269708-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (HRP) |
|||
| MBS6269708-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (PE)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (PE) |
|||
| MBS6269714-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (PE) |
|||
| MBS6269714-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (FITC)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (FITC) |
|||
| MBS6269707-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (FITC) |
|||
| MBS6269707-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (Biotin)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (Biotin) |
|||
| MBS6269706-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (Biotin) |
|||
| MBS6269706-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (MaxLight 405)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 405) |
|||
| MBS6269709-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 405) |
|||
| MBS6269709-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (MaxLight 490)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 490) |
|||
| MBS6269710-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 490) |
|||
| MBS6269710-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (MaxLight 550)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 550) |
|||
| MBS6269711-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 550) |
|||
| MBS6269711-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (MaxLight 650)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 650) |
|||
| MBS6269712-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 650) |
|||
| MBS6269712-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (MaxLight 750)) JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 750) |
|||
| MBS6269713-01mL | MyBiosource | 0.1mL | EUR 890 |
JAM-C (Junctional Adhesion Molecule C, JAM-2, Junctional Adhesion Molecule 3, JAM-3) (MaxLight 750) |
|||
| MBS6269713-5x01mL | MyBiosource | 5x0.1mL | EUR 3865 |
 (AP)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (AP) |
|||
| MBS6456767-02mL | MyBiosource | 0.2mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (AP) |
|||
| MBS6456767-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
 (APC)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (APC) |
|||
| MBS6456768-02mL | MyBiosource | 0.2mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (APC) |
|||
| MBS6456768-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
 (HRP)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (HRP) |
|||
| MBS6456771-02mL | MyBiosource | 0.2mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (HRP) |
|||
| MBS6456771-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
 (PE)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (PE) |
|||
| MBS6456777-02mL | MyBiosource | 0.2mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (PE) |
|||
| MBS6456777-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
 (FITC)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (FITC) |
|||
| MBS6456770-02mL | MyBiosource | 0.2mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (FITC) |
|||
| MBS6456770-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
 (Biotin)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (Biotin) |
|||
| MBS6456769-02mL | MyBiosource | 0.2mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (Biotin) |
|||
| MBS6456769-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
) Human Junctional adhesion molecule B (JAM2) |
|||
| 1-CSB-YP011936HU | Cusabio |
|
|
|
|||
|
Description: Recombinant Human Junctional adhesion molecule B(JAM2),partial expressed in Yeast |
|||
Human Junctional adhesion molecule B (JAM2) |
|||
| 1-CSB-EP011936HU | Cusabio |
|
|
|
|||
|
Description: Recombinant Human Junctional adhesion molecule B(JAM2),partial expressed in E.coli |
|||
) Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-Fc) |
|||
| AP75554 | SAB | 1mg | EUR 3209 |
|
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-Fc) |
|||
| CC52-10ug | Novoprotein | 10ug | EUR 175.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 . |
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-Fc) |
|||
| CC52-1mg | Novoprotein | 1mg | EUR 2739.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 . |
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-Fc) |
|||
| CC52-500ug | Novoprotein | 500ug | EUR 1935.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 . |
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-Fc) |
|||
| CC52-50ug | Novoprotein | 50ug | EUR 363.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 . |
|||
 (MaxLight 405)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 405) |
|||
| MBS6456772-01mL | MyBiosource | 0.1mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 405) |
|||
| MBS6456772-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
 (MaxLight 490)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 490) |
|||
| MBS6456773-01mL | MyBiosource | 0.1mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 490) |
|||
| MBS6456773-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
 (MaxLight 550)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 550) |
|||
| MBS6456774-01mL | MyBiosource | 0.1mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 550) |
|||
| MBS6456774-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
 (MaxLight 650)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 650) |
|||
| MBS6456775-01mL | MyBiosource | 0.1mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 650) |
|||
| MBS6456775-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
 (MaxLight 750)) JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 750) |
|||
| MBS6456776-01mL | MyBiosource | 0.1mL | EUR 980 |
JAM3 (Junctional Adhesion Molecule C, JAM-C, JAM-2, Junctional Adhesion Molecule 3, JAM-3, JAM3) (MaxLight 750) |
|||
| MBS6456776-5x01mL | MyBiosource | 5x0.1mL | EUR 4250 |
) Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-6His) |
|||
| AP75079 | SAB | 1mg | EUR 3209 |
|
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-6His) |
|||
| C359-10ug | Novoprotein | 10ug | EUR 145.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-6His) |
|||
| C359-1mg | Novoprotein | 1mg | EUR 2739.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-6His) |
|||
| C359-500ug | Novoprotein | 500ug | EUR 1935.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
|||
Recombinant Human Junctional Adhesion Molecule B/JAM-B/CD322 (C-6His) |
|||
| C359-50ug | Novoprotein | 50ug | EUR 315.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
|||
) JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS6004595-005mg | MyBiosource | 0.05(mg | EUR 820 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS6004595-5x005mg | MyBiosource | 5x0.05mg | EUR 3535 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS6005117-01mg | MyBiosource | 0.1(mg | EUR 665 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS6005117-5x01mg | MyBiosource | 5x0.1mg | EUR 2850 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS6002216-01mg | MyBiosource | 0.1(mg | EUR 570 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS6002216-5x01mg | MyBiosource | 5x0.1mg | EUR 2410 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS648899-01mg | MyBiosource | 0.1mg | EUR 520 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS648899-5x01mg | MyBiosource | 5x0.1mg | EUR 2185 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS643566-01mg | MyBiosource | 0.1mg | EUR 630 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) |
|||
| MBS643566-5x01mg | MyBiosource | 5x0.1mg | EUR 2680 |
) Human Junctional Adhesion Molecule 2/JAM-B Antibody (Biotin Conjugate) |
|||
| 33424-05121 | AssayPro | 150 ug | EUR 315 |
 APC) JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) APC |
|||
| MBS6137239-01mL | MyBiosource | 0.1(mL | EUR 875 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) APC |
|||
| MBS6137239-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
 (Biotin)) JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (Biotin) |
|||
| MBS6142542-01mL | MyBiosource | 0.1(mL | EUR 875 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (Biotin) |
|||
| MBS6142542-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
 (AP)) JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (AP) |
|||
| MBS6131936-01mL | MyBiosource | 0.1(mL | EUR 875 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (AP) |
|||
| MBS6131936-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
 (FITC)) JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (FITC) |
|||
| MBS6147845-01mL | MyBiosource | 0.1(mL | EUR 875 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (FITC) |
|||
| MBS6147845-5x01mL | MyBiosource | 5x0.1mL | EUR 3800 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (AP) |
|||
| MBS6383355-01mL | MyBiosource | 0.1mL | EUR 920 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (AP) |
|||
| MBS6383355-5x01mL | MyBiosource | 5x0.1mL | EUR 3990 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) APC |
|||
| MBS6383356-01mL | MyBiosource | 0.1mL | EUR 920 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) APC |
|||
| MBS6383356-5x01mL | MyBiosource | 5x0.1mL | EUR 3990 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (Biotin) |
|||
| MBS6383357-01mL | MyBiosource | 0.1mL | EUR 920 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (Biotin) |
|||
| MBS6383357-5x01mL | MyBiosource | 5x0.1mL | EUR 3990 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (FITC) |
|||
| MBS6383358-01mL | MyBiosource | 0.1mL | EUR 920 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (FITC) |
|||
| MBS6383358-5x01mL | MyBiosource | 5x0.1mL | EUR 3990 |
 (HRP)) JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (HRP) |
|||
| MBS6383359-01mL | MyBiosource | 0.1mL | EUR 920 |
JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (HRP) |
|||
| MBS6383359-5x01mL | MyBiosource | 5x0.1mL | EUR 3990 |
 (PE)) JAM2 (Junctional Adhesion Molecule B, JAM-B, Junctional Adhesion Molecule 2, JAM-2, Vascular Endothelial Junction-associated Molecule, VE-JAM, CD322, C21orf43, VEJAM, UNQ219/PRO245) (PE) |
|||
| MBS6383365-01mL | MyBiosource | 0.1mL | EUR 920 |